NeuroPace's RNS System trial showed a strong safety profile and subgroup efficacy in drug-resistant epilepsy, prompting FDA ...

Eamonn started playing rugby when he was six years old and now plays in the second and third team for Huel Tring Rugby.

The Ottawa Hospital is creating a comprehensive Epilepsy Program — a one-stop shop that will be a change-maker for patients.

Following its successful US launch and FDA clearance, Empatica is proud to announce that EpiMonitor, its pioneering epilepsy ...

Empatica announced today that it received CE mark approval for its EpiMonitor epilepsy monitoring solution. EpiMonitor, a ...

NeuroPace has completed the primary endpoint analysis of the one-year data from the first and only clinical study to evaluate neuromodulation therapy for idiopathic generalized epilepsy -- Study met ...

Shares of NeuroPace sank after the company said the study of its RNS system for treating drug-resistant idiopathic generalized epilepsy missed a primary endpoint. The stock was down 37% at $11.15 in ...

NeuroPace has completed the primary endpoint analysis of the one-year data from the first and only clinical study to evaluate neuromodulation therapy for idiopathic generalized epilepsy -- Study ...

A Carlisle man who battled with addiction since the age of 13 was found dead due to drug use in his home, an inquest has heard. Mark Pilling, 45, was found dead by his partner in his home on Partridge ...

Pomerantz LLP is investigating claims on behalf of investors of  NeuroPace, Inc. ("NeuroPace" or the "Company") . Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or ...

Shares of NeuroPace Inc (NASDAQ:NPCE) plummeted 36.1% today after the company reported that its primary effectiveness endpoint for the NAUTILUS study did not reach statistical significance in the ...

From these patients, 6,530 hours of data were recorded over 272 days, including 40 generalised tonic-clonic seizures, also known as 'grand mal' the most serious seizures. Embrace's algorithm was ...